News

  • 19 November 2018

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) (“Axonics”), a medical technology company focused on the design, development and commercialization of innovative and minimally invasive sacral neuromodulation (“SNM”) solutions for the treatment of overactive bladder (“OAB”), fecal incontinence (“FI”), and urinary retention (“UR”), today announced that the underwriters of its initial public offering exercised in full their option to purchase an additional 1,200,000 shares of common stock from Axonics at the initial public offering price of $15.00 per share, less underwriting discounts and commissions.

  • 19 November 2018

    Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform lives of people with serious diseases, today announces it has entered into a new partnership with Genentech, a member of the Roche Group, to expand an existing discovery collaboration.

  • 7 November 2018

    Axonics Modulation Technologies, Inc., (NASDAQ: AXNX), developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, announced today that it has received Health Canadaapproval (Homologation d'un instrument medical) to market its External Trial System.

  • 5 November 2018

    Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX) announced today that its lead product candidate GKT831, a NOX1/4 inhibitor, met both the primary and secondary interim efficacy endpoints with high statistical significance after only 6 weeks of treatment. The data establish GKT831 as an attractive therapeutic option in a broad PBC population and support its development in multiple fibrotic diseases including NASH and IPF. 

  • 2 November 2018

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) (“Axonics”), a medical technology company focused on the design, development and commercialization of innovative and minimally invasive sacral neuromodulation (“SNM”) solutions for the treatment of overactive bladder (“OAB”), fecal incontinence (“FI”), and urinary retention (“UR”), today announced the closing of its initial public offering of 8,000,000 shares of common stock at an initial public offering price of $15.00 per share, raising $120 million in gross proceeds from the offering, before underwriting discounts and commissions and estimated offering expenses. Axonics has also granted the underwriters a 30-day option to purchase an additional 1,200,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares of common stock were offered by Axonics.